Hims & Hers's Peptide Opportunity Remains in Focus

Dow Jones07-10

1214 ET - Hims & Hers Health is likely to beat estimates and raise its full-year guidance when it reports second-quarter results, but its potential opportunity in peptides is the biggest thing on investors' minds, Truist Securities analysts say in a note. The analysts point to credit-card data from June, which shows strong trends in the telehealth company's GLP-1 business as the rest of its business remains stable, they say. However, the stock has gained lately due to enthusiasm around the company's potential in peptides, making for a tough risk-reward setup for shares heading into the Food and Drug Administration's advisory committee meeting later this month, which will consider several peptides, the analysts say. Even if the committee gives a favorable recommendation, Hims likely wouldn't see any meaningful revenue boost from a potential peptide offering before 2028, the analysts say. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

July 09, 2026 12:14 ET (16:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment